Compare GERN & EVER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GERN | EVER |
|---|---|---|
| Founded | 1990 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 928.5M |
| IPO Year | 1996 | 2018 |
| Metric | GERN | EVER |
|---|---|---|
| Price | $1.31 | $19.35 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $2.17 | ★ $27.00 |
| AVG Volume (30 Days) | ★ 8.8M | 544.7K |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 51.85 | ★ 198.86 |
| EPS | N/A | ★ 1.04 |
| Revenue | $1,065,000.00 | ★ $163,349,000.00 |
| Revenue This Year | $26.91 | $14.73 |
| Revenue Next Year | $43.75 | $11.51 |
| P/E Ratio | ★ N/A | $21.95 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.04 | $13.88 |
| 52 Week High | $2.01 | $28.73 |
| Indicator | GERN | EVER |
|---|---|---|
| Relative Strength Index (RSI) | 39.30 | 27.65 |
| Support Level | $1.24 | $14.40 |
| Resistance Level | $1.32 | $20.17 |
| Average True Range (ATR) | 0.07 | 1.20 |
| MACD | -0.02 | -0.41 |
| Stochastic Oscillator | 10.00 | 0.59 |
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
EverQuote Inc operates an online marketplace for insurance shopping, connecting consumers with insurance providers, including carriers and agents. Its marketplace is powered by proprietary data and technology platform that delivers high-intent, pre-validated consumer referrals aligned with insurers underwriting and profitability requirements. The platform provides transparency and campaign management tools, enabling providers to evaluate marketing spend performance and manage return on investment. Consumers can visit insurance provider websites, engage by phone, or submit data to receive quotes. Services are free for consumers, and the company derives revenue principally from consumer inquiries sold as referrals to insurance providers. It derives a majority of revenue from Direct channels.